DNp73 a matter of cancer:: Mechanisms and clinical implications

被引:52
作者
Buhlmann, Sven [1 ]
Puetzer, Brigitte M. [1 ]
机构
[1] Univ Rostock, Sch Med, Dept Venerol & Expt Gene Therapy, Biomed Res Ctr, D-18055 Rostock, Germany
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2008年 / 1785卷 / 02期
关键词
DNp73; oncogene; tumorigenesis; tumor suppressor pathways; differentiation; cancer;
D O I
10.1016/j.bbcan.2008.01.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p53 family proteins carry on a wide spectrum of biological functions from differentiation, cell cycle arrest, apoptosis, and chemosensitivity of tumors. NH2-ten-ninally truncated p73 (referred to as DNp73) acts as a potent inhibitor of all these tumor suppressor properties, implying that it has oncogenic functions in human tumorigenesis. This was favored by the observation that high DNp73 expression levels in a variety of cancers are associated with adverse clinico-pathological characteristics and the response failure to chemotherapy. The actual challenge is the deciphering of the molecular mechanisms by which DNp73 promotes malignancy and to unravel the regulatory pathways for controlling TP73 isoform expression. This review is focused on recent findings leaving no doubt that N-terminally truncated p73 proteins are operative during oncogenesis, thus underscoring its significance as a marker for disease severity in patients and as target for cancer therapy. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:207 / 216
页数:10
相关论文
共 82 条
[1]  
Becker K, 2006, INT J ONCOL, V29, P889
[2]   Regulation of telomerase activity by the p53 family member p73 [J].
Beitzinger, M ;
Oswald, C ;
Beinoraviciute-Kellner, R ;
Stiewe, T .
ONCOGENE, 2006, 25 (06) :813-826
[3]   DNp73α protects myogenic cells from apoptosis [J].
Belloni, L. ;
Moretti, F. ;
Merlo, P. ;
Damalas, A. ;
Costanzo, A. ;
Blandino, G. ;
Levrero, M. .
ONCOGENE, 2006, 25 (25) :3606-3612
[4]   p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis [J].
Bergamaschi, D ;
Gasco, M ;
Hiller, L ;
Sullivan, A ;
Syed, N ;
Trigiante, G ;
Yulug, I ;
Merlano, M ;
Numico, G ;
Comino, A ;
Attard, M ;
Reelfs, O ;
Gusterson, B ;
Bell, AK ;
Heath, V ;
Tavassoli, M ;
Farrell, PJ ;
Smith, P ;
Lu, X ;
Crook, T .
CANCER CELL, 2003, 3 (04) :387-402
[5]   Roles for p53 and p73 during oligodendrocyte development [J].
Billon, N ;
Terrinoni, A ;
Jolicoeur, C ;
McCarthy, A ;
Richardson, WD ;
Melino, G ;
Raff, M .
DEVELOPMENT, 2004, 131 (06) :1211-1220
[6]   p73 and p53 pathway in human breast cancers [J].
Bozzetti, Cecilia ;
Nizzoli, Rita ;
Musolino, Antonino ;
Martella, Eugenia M. ;
Crafa, Pellegrino ;
Lagrasta, Costanza A. ;
Camisa, Roberta ;
Bonati, Antonio ;
Lunghi, Paolo ;
Ardizzoni, Andrea .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) :1451-1453
[7]   p53 family members in myogenic differentiation and rhabdomyosarcoma development [J].
Cam, Hakan ;
Griesmann, Heidi ;
Beitzinger, Michaela ;
Hofmann, Lars ;
Beinoraviciute-Kellner, Rasa ;
Sauer, Markus ;
Huettinger-Kirchhof, Nicole ;
Oswald, Claudia ;
Friedl, Peter ;
Gattenloehner, Stefan ;
Burek, Christof ;
Rosenwald, Andreas ;
Stiewe, Thorsten .
CANCER CELL, 2006, 10 (04) :281-293
[8]   Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients [J].
Casciano, I ;
Mazzocco, K ;
Boni, L ;
Pagnan, G ;
Banelli, B ;
Allemanni, G ;
Ponzoni, M ;
Tonini, GP ;
Romani, M .
CELL DEATH AND DIFFERENTIATION, 2002, 9 (03) :246-251
[9]   p73 is transcriptionally regulated by DNA damage, p53, and p73 [J].
Chen, XB ;
Zheng, YM ;
Zhu, JH ;
Jiang, JY ;
Wang, J .
ONCOGENE, 2001, 20 (06) :769-774
[10]   Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer.: Evidence for their role as epigenetic p53 inhibitors in vivo [J].
Concin, N ;
Becker, K ;
Slade, N ;
Erster, S ;
Mueller-Holzner, E ;
Ulmer, H ;
Daxenbichler, G ;
Zeimet, A ;
Zeillinger, R ;
Marth, C ;
Moll, UM .
CANCER RESEARCH, 2004, 64 (07) :2449-2460